多西他赛联合替吉奥新辅助化疗对进展期胃癌的疗效及血清肿瘤标志物的影响  

The Effect of Docetaxel Combined with Neoadjuvant Chemotherapy with Tigio on Disease Control and Serum Tumor Markers in Patients with Advanced Gastric Cancer

作　　者：肖开 刘永青[1] 吴通[1] XIAO Kai;LIU Yongqing;WU Tong(Zhengzhou Third People's Hospital,Zhengzhou,450000)

机构地区：[1]郑州市第三人民医院,450000

出　　处：《实用癌症杂志》2024年第10期1704-1706,共3页The Practical Journal of Cancer

摘　　要：目的探讨多西他赛联合替吉奥新辅助化疗对进展期胃癌患者的疗效。方法选取84例进展期胃癌患者,依据随机数表法分为2组,各42例,对照组接受5-氟尿嘧啶+顺铂新辅助化疗,观察组接受多西他赛+替吉奥新辅助化疗,均治疗3个周期,分析疾病控制效果,比较两组治疗前与治疗3个周期后的血清肿瘤标志物[糖类抗原(CA199)、癌胚抗原(CEA)]变化情况,记录不良反应出现情况。结果观察组疾病控制率为54.76%,略高于对照组的42.86%,但差异无统计学意义(P>0.05);治疗前两组CA199、CEA值对比,差异无统计学意义(P>0.05);但治疗3个周期后,观察组均低于对照组,差异有统计学意义(P<0.05);此外,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论进展期胃癌患者经多西他赛联合替吉奥新辅助化疗可有效保证治疗效果,降低CA199、CEA水平,具有一定安全性。Objective To investigate the efficacy of docetaxel combined with Tigioneoadjuvant chemotherapy in patients with advanced gastric cancer.Methods A total of 84 patients with advanced gastric cancer were selected and divided into 2 groups(42 cases each)according to random number table method.The control group received 5-fluorouracil+cisplatin neoadjuvant chemotherapy,and the observation group received docetaxel+Tighio neoadjuvant chemotherapy for 3 cycles,and the disease control effect was analyzed.The changes of serum tumor markers(carbohydrate antigen(CA199)and carcinoembryonic antigen(CEA))before and after 3 cycles of treatment were compared between the 2 groups,and the occurrence of adverse reactions was recorded.Results The disease control rate of the observation group was 54.76%,slightly higher than that of the control group(42.86%),but the difference was not statistically significant(P>0.05).There was no significant difference in CA199 and CEA values between the 2 groups before treatment(P>0.05).However,after 3 cycles of treatment,the observation group was lower than control group,the difference was statistically significant(P<0.05).In addition,there was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Docetaxel combined with Tiggio neoadjuvant chemotherapy can effectively guarantee the therapeutic effect and reduce the levels of CA199 and CEA in patients with advanced gastric cancer,with certain safety.

关 键 词：进展期胃癌 多西他赛 替吉奥 新辅助化疗 血清肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]